Zhang Chi, Li Jia-Wen, Wu Zhao, Zhao Hong, Wang Gui-Qiang
Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District, Beijing, China.
Peking University International Hospital, Beijing, China.
J Clin Transl Hepatol. 2021 Oct 28;9(5):615-625. doi: 10.14218/JCTH.2020.00136. Epub 2021 May 6.
Chronic hepatitis B is the main cause of liver cancer. However, the most neglected group has been treatment-naive chronic hepatitis B patients with normal alanine aminotransferase (ALT). People have tended to subjectively assume that the liver lesions of these patients are not serious and do not need antiviral treatment. However, the truth is not as optimistic as we thought. We aimed in this study to analyze the proportion of significant inflammation or fibrosis in aforementioned patients.
Medline, Embase, and Cochrane Library were searched up to January 10 2020, to identify studies of these patients with liver biopsy. The double arcsine method was used with a random-effect model to combine the proportion of significant inflammation or fibrosis. Potential heterogeneity was explored by subgroup analysis and meta-regression. Outcome of interests included the proportion of significant inflammation or fibrosis and cirrhosis. The secondary outcome was to find the risk factors of significant histological changes.
Nineteen eligible studies, with 2,771 participants, were included. The pooled proportion of significant inflammation or fibrosis was 35% [95% confidence interval (CI): 27 to 43] and 30% (95% CI: 25 to 36), respectively. The pooled proportion of cirrhosis was 3% [95% CI: 1 to 5, (12 studies; 1,755 participants)]. In subgroup analysis, old age [vs. young (<40 years-old), 44% vs. 26%, =0.012] was significantly associated with higher fibrosis stage as well as cirrhosis [vs. young (<40 years-old), 4.8% vs. 1.8%, <0.001].
About 1/3 of the treatment-naive chronic hepatitis B patients with normal ALT show significant histological changes, and some even have cirrhosis.
慢性乙型肝炎是肝癌的主要病因。然而,最被忽视的群体是谷丙转氨酶(ALT)正常的未经治疗的慢性乙型肝炎患者。人们往往主观地认为这些患者的肝脏病变不严重,不需要抗病毒治疗。然而,事实并不像我们想象的那么乐观。我们在本研究中的目的是分析上述患者中显著炎症或纤维化的比例。
检索截至2020年1月10日的Medline、Embase和Cochrane图书馆,以确定对这些患者进行肝活检的研究。采用双反正弦法和随机效应模型来合并显著炎症或纤维化的比例。通过亚组分析和meta回归探讨潜在的异质性。感兴趣的结果包括显著炎症或纤维化以及肝硬化的比例。次要结果是找出显著组织学变化的危险因素。
纳入了19项符合条件的研究,共2771名参与者。显著炎症或纤维化的合并比例分别为35%[95%置信区间(CI):27%至43%]和30%(95%CI:25%至36%)。肝硬化的合并比例为3%[95%CI:1%至5%,(12项研究;1755名参与者)]。在亚组分析中,老年[与年轻(<40岁)相比,44%对26%,P = 0.012]与更高的纤维化阶段以及肝硬化显著相关[与年轻(<40岁)相比,4.8%对1.8%,P < 0.001]。
约三分之一的ALT正常的未经治疗的慢性乙型肝炎患者表现出显著的组织学变化,有些甚至患有肝硬化。